

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

CLINICAL BENEFIT	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input checked="" type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
Effective Date:	2/1/2024

[POLICY RATIONALE](#)
[DISCLAIMER](#)
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)
[DEFINITIONS](#)
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)
[BENEFIT VARIATIONS](#)
[REFERENCES](#)

I. POLICY

Endovascular occlusion of the ovarian vein and internal iliac veins for the treatment of pelvic congestion syndrome is considered **investigational** as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

II. PRODUCT VARIATIONS

[Top](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross please see additional information below, and subject to benefit variations as discussed in Section VI below.

FEP PPO - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at:

<https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

III. DESCRIPTION/BACKGROUND

[Top](#)

Pelvic congestion syndrome

Pelvic congestion syndrome is a chronic pelvic pain syndrome of variable location and intensity, which is associated with dyspareunia and postcoital pain and aggravated by standing. The syndrome occurs during the reproductive years, and pain is often greater before or during menses. The underlying etiology is thought to be related to varices of the ovarian veins, leading to pelvic vascular congestion. Because there are many etiologies of chronic pelvic pain, the pelvic congestion syndrome is often a diagnosis of exclusion, with the identification of varices using a variety of imaging methods, such as magnetic resonance imaging, computed tomography scanning, or contrast venography. However, the syndrome is still not well defined and it is unclear whether pelvic congestion syndrome causes chronic pelvic pain. Although venous reflux is common, not all women with this condition experience chronic pelvic pain and, conversely, chronic pelvic pain is reported by women without pelvic congestion syndrome.

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

Treatment

Initial treatment of pelvic congestion syndrome includes psychotherapy and medical therapy (e.g., nonsteroidal anti-inflammatory drugs) and hormonal therapy. For patients who fail initial therapy, surgical ligation of the ovarian vein may be considered. Embolization therapy and/or sclerotherapy of the ovarian and internal iliac veins has been proposed as an alternative to surgical ovarian vein ligation. Endovascular occlusion can be performed using a variety of materials including coils, vascular plugs, glue, liquid embolic agents, and gelatin sponge or powder (Gelfoam).

Regulatory Status

Ovarian and internal iliac vein embolization is a surgical procedure and as such is not subject to regulation by U.S. Food and Drug Administration.

Various products (eg, coils, vascular plugs, glue, liquid embolic agents, Gelfoam) and/or delivery-assist devices would be used to embolize the vein(s), and they would be subject to Food and Drug Administration regulation. Several products have been cleared for marketing by the Food and Drug Administration through the 510(k) process for uterine fibroid embolization (eg, Embosphere® Microspheres, Cook Incorporated Polyvinyl Alcohol Foam Embolization Particles) and/or embolization of hypervascular tumors and arteriovenous malformations (eg, Contour® Emboli PVA). Several embolization delivery systems have also been cleared via the 510(k) process for arterial and venous embolization in the peripheral vasculature featuring vascular plugs (eg, ArtVentive Medical Group, Inc. Endoluminal Occlusion System [EOS™]) or coils (eg, Cook Incorporated MReye® Flipper®). FDA product code: KRD.

In November 2004, the sclerosant agent Sotradecol® (sodium tetradecyl sulfate injection) was approved by the U.S. Food and Drug Administration for use in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves (ANDA 040541).

IV. RATIONALE

[Top](#)

Summary of Evidence

For individuals who have pelvic congestion syndrome who receive ovarian and/or internal iliac vein endovascular occlusion, the evidence includes randomized studies, comparative studies, case series and systematic reviews. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. Systemic reviews of prospective and retrospective data, , as well as more recently published retrospective cohort studies, indicate consistently high clinical success rates (primarily in the form of significant pain reduction) ranging from 63.7% to 100% ovarian and/or internal iliac vein endovascular occlusion at short-term, long-term, or overall follow-up. In a randomized trial of embolization with vascular plugs or coils in patients with pelvic congestion syndrome, adverse events were reported in 22% and 10% of patients, respectively. A retrospective analysis comparing coil embolization to endoscopic resection determined that resection is associated with significantly shorter times to postprocedural pain relief and avoidance of postembolization syndrome. Moreover, definitions of pelvic congestion syndrome

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

vary, making it challenging to define a patient population with symptoms arising from pelvic congestion. Randomized controlled trials using well-defined eligibility criteria and relevant comparators are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

V. DEFINITIONS

[Top](#)

DYSPAREUNIA is pain in the labia, vagina, or pelvis during or after sexual intercourse.

INTERNAL ILIAC VEIN (HYPOGASTRIC VEIN) are the veins that originate deep in the pelvic region and extend to the lower portion of the abdomen, where they are joined with the right and left iliac veins, that together form the common iliac veins.

OVARIAN VEIN is one of a pair of veins that emerge from the broad ligament near the ovaries and the uterine tubes.

THERAPEUTIC EMBOLIZATION is the obstruction of a blood vessel by intentionally injected material.

VARICES are tortuous, dilated veins.

VI. BENEFIT VARIATIONS

[Top](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's health benefit plan. Benefit determinations should be based in all cases on the applicable health benefit plan language. Medical policies do not constitute a description of benefits. A member's health benefit plan governs which services are covered, which are excluded, which are subject to benefit limits and which require preauthorization. There are different benefit plan designs in each product administered by Capital Blue Cross. Members and providers should consult the member's health benefit plan for information or contact Capital Blue Cross for benefit information.

VII. DISCLAIMER

[Top](#)

Capital Blue Cross's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. If a provider or a member has a question concerning the application of this medical policy to a specific member's plan of benefits, please contact Capital Blue Cross' Provider Services or Member Services. Capital Blue Cross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

[Top](#)

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Endovascular occlusion of the ovarian vein and internal iliac veins for the treatment of pelvic congestion syndrome is considered investigational; therefore, the following codes are not covered when used for embolization and/or sclerotherapy of the ovarian and internal iliac veins for the treatment of pelvic congestion syndrome:

Procedure Codes							
37241							

IX. REFERENCES

[TOP](#)

1. Knuttinen MG, Machan L, Khilnani NM, et al. Diagnosis and Management of Pelvic Venous Disorders: AJR Expert Panel Narrative Review. *AJR Am J Roentgenol.* Apr 05 2023. PMID 37095667
2. Meissner MH, Khilnani NM, Labropoulos N, et al. The Symptoms-Varices-Pathophysiology classification of pelvic venous disorders: A report of the American Vein Lymphatic Society International Working Group on Pelvic Venous Disorders. *J Vasc Surg Venous Lymphat Disord.* May 2021; 9(3): 568-584. PMID 33529720
3. Borghi C, Dell'Atti L. Pelvic congestion syndrome: the current state of the literature. *Arch Gynecol Obstet.* Feb 2016; 293(2): 291-301. PMID 26404449
4. Bendek B, Afuape N, Banks E, et al. Comprehensive review of pelvic congestion syndrome: causes, symptoms, treatment options. *Curr Opin Obstet Gynecol.* Aug 2020; 32(4): 237-242. PMID 32487799
5. Ball E, Khan KS, Meads C. Does pelvic venous congestion syndrome exist and can it be treated?. *Acta Obstet Gynecol Scand.* May 2012; 91(5): 525-8. PMID 22268663
6. Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: a systematic review of diagnosis and management. *Obstet Gynecol Surv.* May 2010; 65(5): 332-40. PMID 20591203
7. Brown CL, Rizer M, Alexander R, et al. Pelvic Congestion Syndrome: Systematic Review of Treatment Success. *Semin Intervent Radiol.* Mar 2018; 35(1): 35-40. PMID 29628614
8. Mahmoud O, Vikatmaa P, Aho P, et al. Efficacy of endovascular treatment for pelvic congestion syndrome. *J Vasc Surg Venous Lymphat Disord.* Jul 2016; 4(3): 355-70. PMID 27318059
9. Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. *Tohoku J Exp Med.* Nov 2003; 201(3): 131-8. PMID 14649734
10. Guirola JA, Sanchez-Ballestin M, Sierre S, et al. A Randomized Trial of Endovascular Embolization Treatment in Pelvic Congestion Syndrome: Fibered Platinum Coils versus Vascular Plugs with 1-Year Clinical Outcomes. *J Vasc Interv Radiol.* Jan 2018; 29(1): 45-53. PMID 29174618
11. Gavrilov SG, Sazhin A, Krasavin G, et al. Comparative analysis of the efficacy and safety of endovascular and endoscopic interventions on the gonadal veins in the

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

treatment of pelvic congestion syndrome. J Vasc Surg Venous Lymphat Disord. Jan 2021; 9(1): 178-186. PMID 32464289

12. Liu J, Han L, Han X. The Effect of a Subsequent Pregnancy After Ovarian Vein Embolization in Patients with Infertility Caused by Pelvic Congestion Syndrome. *Acad Radiol. Oct 2019; 26(10): 1373-1377. PMID 30660471*
13. Hocquelet A, Le Bras Y, Balian E, et al. Evaluation of the efficacy of endovascular treatment of pelvic congestion syndrome. *Diagn Interv Imaging. Mar 2014; 95(3): 301-6. PMID 24183954*
14. Nasser F, Cavalcante RN, Affonso BB, et al. Safety, efficacy, and prognostic factors in endovascular treatment of pelvic congestion syndrome. *Int J Gynaecol Obstet. Apr 2014; 125(1): 65-8. PMID 24486124*
15. Laborda A, Medrano J, de Blas I, et al. Endovascular treatment of pelvic congestion syndrome: visual analog scale (VAS) long-term follow-up clinical evaluation in 202 patients. *Cardiovasc Intervent Radiol. Aug 2013; 36(4): 1006-14. PMID 23456353*
16. Gandini R, Chiocchi M, Konda D, et al. Transcatheter foam sclerotherapy of symptomatic female varicocele with sodium-tetradecyl-sulfate foam. *Cardiovasc Intervent Radiol. Jul-Aug 2008; 31(4): 778-84. PMID 18172712*
17. Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. *Cardiovasc Intervent Radiol. Jul-Aug 2007; 30(4): 655-61. PMID 17468903*
18. Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: long-term results. *J Vasc Interv Radiol. Feb 2006; 17(2 Pt 1): 289-97. PMID 16517774*
19. Society of Interventional Radiology (SIR). Diseases and conditions: Chronic pelvic pain (pelvic congestion syndrome) [Patient Center]. n.d.
20. Corrêa MP, Bianchini L, Saleh JN, Noel RS, Bajerski JC. Pelvic congestion syndrome and embolization of pelvic varicose veins. *J Vasc Bras. 2019;18:e20190061. Published 2019 Nov 8. doi:10.1590/1677-5449.190061 PMID: 31762775*
21. Brown CL, Rizer M, Alexander R, Sharpe EE 3rd, Rochon PJ. Pelvic Congestion Syndrome: Systematic Review of Treatment Success. *Semin Intervent Radiol. 2018;35(1):35-40. doi:10.1055/s-0038-1636519 PMID 29628614*
22. Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg. May 2011; 53(5 Suppl): 2S-48S. PMID 21536172*
23. Lopez AJ. Female Pelvic Vein Embolization: Indications, Techniques, and Outcomes. *Cardiovasc Intervent Radiol. 2015;38(4):806-820. doi:10.1007/s00270-015-1074-7. PMID 25804635*
24. Kashaf E, Evans E, Patel N, Agrawal D, Hemingway AP. Pelvic venous congestion syndrome: female venous congestive syndromes and endovascular treatment options. *CVIR Endovasc. 2023;6(1):25. Published 2023 Apr 20. doi:10.1186/s42155-023-00365-y. PMID: 37076700*
25. Blue Cross Blue Shield Association Medical Policy Reference Manual. 4.01.18, Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome. September 2022.

MEDICAL POLICY

POLICY TITLE	OVARIAN AND INTERNAL ILIAC VEIN ENDOVASCULAR OCCLUSION AS A TREATMENT OF PELVIC CONGESTION SYNDROME
POLICY NUMBER	MP 1.116

X. POLICY HISTORY

[Top](#)

MP-1.116	7/14/2020 Consensus Review. Policy Statement unchanged. Policy title and language revised from “embolization” to “endovascular occlusion” for clarification. FEP variation removed as FEP policy no longer in effect. Description/Background and Rationale updated. References added.
	10/15/2021 Consensus Review. Policy statement unchanged. Rationale and references updated.
	12/13/2022 Consensus Review. Policy statement unchanged. Definitions and references updated.
	09/22/2023 Consensus Review. Policy statement is unchanged. Updated rationale and references.

[Top](#)

Health care benefit programs issued or administered by Capital Blue Cross and/or its subsidiaries, Capital Advantage Insurance Company[®], Capital Advantage Assurance Company[®] and Keystone Health Plan[®] Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies